Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País como assunto
Tipo de documento
Intervalo de ano de publicação
1.
J Antimicrob Chemother ; 78(5): 1175-1181, 2023 05 03.
Artigo em Inglês | MEDLINE | ID: mdl-36897327

RESUMO

OBJECTIVES: Standard once-daily dosing of ceftriaxone may not lead to adequate antibiotic exposure in all cases of Staphylococcus aureus bacteraemia (SAB). Therefore, we compared clinical effectiveness of empirical antibiotic treatment with flucloxacillin, cefuroxime and ceftriaxone in adult patients with MSSA bacteraemia. METHODS: We analysed data from the Improved Diagnostic Strategies in Staphylococcus aureus bacteraemia (IDISA) study, a multicentre prospective cohort study of adult patients with MSSA bacteraemia. Duration of bacteraemia and 30 day SAB-related mortality were compared between the three groups using multivariable mixed-effects Cox regression analyses. RESULTS: In total, 268 patients with MSSA bacteraemia were included in the analyses. Median duration of empirical antibiotic therapy was 3 (IQR 2-3) days in the total study population. Median duration of bacteraemia was 1.0 (IQR 1.0-3.0) day in the flucloxacillin, cefuroxime and ceftriaxone groups. In multivariable analyses, neither ceftriaxone nor cefuroxime was associated with increased duration of bacteraemia compared with flucloxacillin (HR 1.08, 95% CI 0.73-1.60 and HR 1.22, 95% CI 0.88-1.71). In multivariable analysis, neither cefuroxime nor ceftriaxone was associated with higher 30 day SAB-related mortality compared with flucloxacillin [subdistribution HR (sHR) 1.37, 95% CI 0.42-4.52 and sHR 1.93, 95% CI 0.67-5.60]. CONCLUSIONS: In this study, we could not demonstrate a difference in duration of bacteraemia and 30 day SAB-related mortality between patients with SAB empirically treated with flucloxacillin, cefuroxime or ceftriaxone. Since sample size was limited, it is possible the study was underpowered to find a clinically relevant effect.


Assuntos
Bacteriemia , Infecções Estafilocócicas , Adulto , Humanos , Staphylococcus aureus , Meticilina/uso terapêutico , beta-Lactamas/uso terapêutico , Cefuroxima/uso terapêutico , Floxacilina/uso terapêutico , Bacteriemia/epidemiologia , Infecções Estafilocócicas/epidemiologia , Ceftriaxona/uso terapêutico , Estudos Prospectivos , Antibacterianos/uso terapêutico
2.
Ned Tijdschr Geneeskd ; 149(48): 2687-9, 2005 Nov 26.
Artigo em Holandês | MEDLINE | ID: mdl-16358620

RESUMO

A 34-year-old woman originally from Ghana was given efavirenz as antiretroviral therapy. One week later she was found to be in a psychotic state with paranoid hallucinations and anxiety; she then stabbed a nurse. The literature indicates that female patients of African origin appear to be more susceptible to the side effects of efavirenz due to genetically reduced clearance and therefore higher serum levels.


Assuntos
Fármacos Anti-HIV/efeitos adversos , População Negra , Oxazinas/efeitos adversos , Transtornos Psicóticos/etiologia , Adulto , Alcinos , Fármacos Anti-HIV/farmacocinética , Fármacos Anti-HIV/uso terapêutico , Benzoxazinas , População Negra/genética , Ciclopropanos , Feminino , Gana/etnologia , Infecções por HIV/tratamento farmacológico , Humanos , Taxa de Depuração Metabólica/genética , Países Baixos , Oxazinas/farmacocinética , Oxazinas/uso terapêutico , Transtornos Psicóticos/etnologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa